qoosa.com

© tmaioli

Biotech companies Bharat Biotech, Panacea Biotech and Serum Institute have agreed to supply NGO GAVI with rotavirus and pentavalent vaccines for kids at substantially discounted rates. The biotech firms agreed to cut prices on vaccines that helped prevent pertussis, hepatitis B, diphtheria, tetanus, and Haemophilus influenzae type b. The NGO is trying to cut down the cost of immunizing a child to $3 and it is supported by Bharat Biotech, but the plan is take 4-5 more years to materialize as Bharat Biotech is yet to commercialize its vaccines.
The biotech firms had slashed their prices by almost 40-50% in response to a tender by GAVI, and if the NGO succeeds in getting the vaccines at $2.50, there will be a significant impact on world health.

© tmaioli

Sixteen biotech companies had the chance to pitch to potential investors as their innovative technologies were showcased at Babraham Research Campus.
The biotech companies – including three based at the campus – were seeking investment of between £250,000 and £17 million from 40 biotech-focused investor groups.
The campus plays a key role bringing together entrepreneurs and investors through events like this and we hope the forum will have catalysed conversations leading to the financing of early-stage biotech ventures.
The overall quality of presentations was high and we met investors actively seeking to deploy capital in biotech companies . We have started several promising discussions.
Babraham biotech newcomer Cell Guidance Systems was among the firms pitching at the event.
The other Babraham biotech firms involved were Phico Therapeutics and Senexis, which was seeking £17 million to fund clinical development of its treatments and diagnostics for Alzheimer's disease.

© CarbonNYC

DUSA Pharmaceuticals (DUSA) is a small-cap biotechnology company that has recently turned profitable, presenting an investment with fantastic return opportunities. It boasts rapidly increasing sales and a gross margin that exceeds 80%. The company is an integrated dermatological biotechnology company whose main products treat the common skin condition actinic keratoses (AK), which are precancerous lesions caused by sun exposure.

AKs areresponsible for over 8 million visits to dermatologists annually, and that number is growing quickly. DUSA has what appears to be a superior treatment option in this fast growing market, with the only side effects being slight sensitivity. 2010 was the first profitable year in the company's history, and sales have continued to increase at a compound annual growth rate of nearly 30%. They currently have only 5% of market share, so there is significant room for growth in the stock.